Mark Chin

Mark Chin, listed as senior executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Harpoon Therapeutics, Inc., Pyxis Oncology, Inc. and Iterum Therapeutics plc. Over a trading history stretching from 16 July 2021 to 8 March 2024, the count stands at 12 filings.

In open-market terms, that means 1 purchase worth €6.8M on one side and 1 sale worth €4.9M on the other. Purchases outweigh sales by €1.9M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 7 share grants and 2 option exercises.

Most recently, on 11 March 2024, the filings show a share grant in Harpoon Therapeutics, Inc. The most recent open-market purchase was published on 28 July 2021, 1,908 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.